Bastiaan Sallevelt

25 General Introduction 17. Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: A systematic review of systematic reviews. Eur J Public Health 2019;29(1):182–9. 18. Bezerra de Souza DL, Oliveras-Fabregas A, Espelt A, Bosque-Prous M, de Camargo Cancela M, Teixidó-Compañó E, et al. Multimorbidity and its associated factors among adults aged 50 and over: A cross-sectional study in 17 European countries. PLoS One 2021;16:1–10. 19. Moen J, Antonov K, Larsson CA, Lindblad U, Nilsson JLG, Råstam L, et al. Factors associated with multiple medication use in different age groups. Ann Pharmacother 2009;43(12):1978–85. 20. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: A systematic review. Health Qual Life Outcomes 2004;20:2:51. 21. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:1–10. s12877-017-0621-2. 22. Mehta RS, Kochar BD, Kennelty K, Ernst ME, Chan AT. Emerging approaches to polypharmacy among older adults. Nat Aging 2021;1:347–56. s43587-021-00045-3. 23. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 2018;17:1185–96. 24. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013;381:752–62. 25. Marengoni A, Onder G. Guidelines, polypharmacy and drug-drug interactions in patients with multimorbidity. Br Med J 2015;350:h1059. 26. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol 2004;57(1):6–14. 27. World Health Organization. Medication errors: Technical Series on Safer Primary Care 2016. (accessedMay 30, 2022). 28. Ministerie van Volksgezondheid Welzijn en Sport. HARM-WRESTLING. Een voorstel van de Expertgroep Medicatieveiligheid m.b.t. concrete interventies die de extramurale medicatieveiligheid op korte termijn kunnen verbeteren. Den Haag, 2009. 29. Warlé-van Herwaarden MF, Kramers C, Sturkenboom MC, van den Bemt PMLA, De Smet PAGM. Targeting Outpatient Drug Safety. Drug Saf 2012;35:245–59. https://doi. org/10.2165/11596000-000000000-00000. 30. SturkenboomMC, Vanrolleghem A, van den Bemt PM, de Smet PA, Hek K. Eindrapport: Vervolgonderzoek Medicatieveiligheid 2017:1–129. vervolgonderzoek-medicatieveiligheid-eindrapport (accessed May 30, 2022). 31. Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol 2014;77:1073–82. https://doi. org/10.1111/bcp.12292. 32. Beer C, Hyde Z, Almeida OP, Norman P, Hankey GJ, Yeap BB, et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: An observational study. Br J Clin Pharmacol 2011;71:592–9. 1